Renal Transplant Nursing Guide

Renal Transplantation — Key Concepts

Kidney transplantation is the treatment of choice for end-stage renal disease (ESRD), providing better quality of life and survival compared to dialysis. GCC countries have active transplant programmes, particularly Saudi Arabia, UAE, and Qatar.

Types of Transplant

Type	Source	Key Points
Living-related donor (LRD)	First-degree relative	Best outcomes — HLA match, shorter ischaemia time, elective timing
Living-unrelated donor (LURD)	Spouse, friend	Good outcomes; HLA match less perfect
Deceased donor (cadaveric)	Brain-dead or cardiac death (DCD)	Longer waiting time; more delayed graft function risk

Indications for Transplant Referral

CKD stage 4–5 (eGFR <20 mL/min) — refer early (pre-emptive transplant preferred)
Already on haemodialysis or peritoneal dialysis
Causes: diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy, PCKD, alport syndrome

Pre-emptive transplantation (before starting dialysis) has the best outcomes. Early referral is therefore a nursing advocacy priority — identify CKD stage 4 patients and ensure timely specialist referral.

Post-Operative Nursing Care

Immediate Post-Op (ICU/High Dependency)

Vital signs every 15–30 minutes for first 4 hours; then hourly
Urine output — PRIMARY monitoring parameter: UO should be 200–1000 mL/hr immediately post-op from "diuresis" as graft begins working; replace volume mL for mL with IV fluids if output >200 mL/hr
IV fluid protocol: 0.9% NaCl mL:mL replacement of hourly UO + insensible losses
Urethral catheter in situ — ensure unobstructed drainage; clots can block catheter
Wound drain: document output; signs of haematoma (sudden pain + fall in Hb)
Pain management: regular paracetamol + PCA morphine; avoid NSAIDs (nephrotoxic)

Delayed Graft Function (DGF)

DGF = need for dialysis in first week post-transplant. Occurs in 20–30% of deceased donor transplants. Causes: prolonged cold ischaemia, donor age/comorbidities, ATN. Management: continue dialysis support; most resolve within 1–3 weeks.

Key Post-Transplant Monitoring

Parameter	Frequency	Target/Action
Urine output	Hourly post-op	Anuria = emergency — call transplant team
Serum creatinine/eGFR	Daily for 1 week; then 3× weekly	Rising creatinine = rejection/DGF/infection
Tacrolimus trough level	Daily initially; then before each dose	Target varies by protocol (typically 8–12 ng/mL first month; 5–8 ng/mL thereafter)
FBC, U&E, LFTs	Daily initially	Anaemia, electrolytes, drug toxicity
Weight	Daily	Fluid balance; oedema

Immunosuppression

Triple therapy is standard: calcineurin inhibitor + antimetabolite + corticosteroid.

Drug	Class	Key Side Effects & Monitoring
Tacrolimus (FK506)	Calcineurin inhibitor	Nephrotoxicity, neurotoxicity (tremor), diabetes, hypertension, hair loss; trough level monitoring essential; narrow therapeutic index
Cyclosporin	Calcineurin inhibitor (older)	Nephrotoxicity, hypertension, hirsutism, gum hyperplasia; increasingly replaced by tacrolimus
Mycophenolate mofetil (MMF)	Antimetabolite	GI side effects (nausea, diarrhoea), leucopenia; teratogenic — reliable contraception essential
Prednisolone	Corticosteroid	Cushing's, osteoporosis, hyperglycaemia, infection, avascular necrosis of femoral head; high dose in acute rejection
Azathioprine	Antimetabolite	Bone marrow suppression; check TPMT enzyme before starting (risk of severe toxicity)
Sirolimus/Everolimus	mTOR inhibitor	Poor wound healing, hyperlipidaemia; not used in first month post-transplant

Tacrolimus Monitoring — Critical Points

Take blood for trough level before morning dose (12-hour trough)
Consistent timing — administer at same time each day
Drug interactions significantly alter tacrolimus levels:
- INCREASE levels: azole antifungals, diltiazem, verapamil, erythromycin, grapefruit juice
- DECREASE levels: rifampicin, phenytoin, carbamazepine, St John's Wort
Signs of tacrolimus toxicity: tremor, confusion, nephrotoxicity, hypertension, hyperglycaemia

Infection risk: Immunosuppressed patients are at high risk of opportunistic infections — CMV, PCP (Pneumocystis), fungal, and reactivation of TB. Prophylaxis protocols: co-trimoxazole for PCP, valganciclovir for CMV in high-risk patients, fluconazole for fungal.

Types of Rejection

Hyperacute Rejection

Timing: Minutes to hours in theatre

Mechanism: Pre-formed recipient antibodies against donor ABO/HLA antigens — vascular thrombosis → graft necrosis

Prevented by: ABO matching and crossmatch before transplant. Now extremely rare in modern transplant practice.

Treatment: Immediate graft nephrectomy — no reversal possible

Acute Rejection

Timing: Days to weeks (most common 1–3 weeks)

Types:

Acute cellular rejection (T-cell mediated) — most common; treated with high-dose IV methylprednisolone
Acute antibody-mediated rejection (ABMR) — more severe; requires plasmapheresis + IVIG + rituximab

Signs: Rising creatinine, oliguria, graft tenderness/swelling, fever

Biopsy: Required to confirm type and guide treatment

Chronic Rejection (Chronic Allograft Nephropathy)

Timing: Months to years

Mechanism: Progressive fibrosis from repeated subclinical immune injury

Features: Gradual creatinine rise, proteinuria, hypertension

Treatment: Optimise immunosuppression, control BP, treat proteinuria (ACEi/ARB); no definitive reversal — eventual graft failure

Nursing Response to Suspected Rejection

Alert transplant team immediately (rising creatinine, oliguria, graft pain)
Ensure IV access; prepare for IV methylprednisolone infusion
Strict fluid balance and monitoring
Biopsy preparation: consent, clotting screen, FBC, group and save
Post-biopsy: bed rest 4–6 hours, monitor for haematuria, haematoma, pain

GCC Context & Islamic Perspectives on Transplantation

Islamic ruling on organ donation: The majority of Islamic scholars and GCC national fatawa councils (including Saudi Arabia's Senior Council of Scholars, Fiqh Academy of the OIC) permit organ donation — both living donor and deceased (brain death accepted as legal death in Islamic jurisprudence in most GCC countries). This has enabled substantial growth of transplant programmes across the GCC.
Saudi Arabia's transplant programme: One of the largest in the Middle East; Saudi Center for Organ Transplantation (SCOT) manages the national registry. King Faisal Specialist Hospital Riyadh performs the majority of transplants.
Consanguinity considerations: High rates of consanguineous marriages in GCC populations increase living-related donor matches within families; also increases risk of hereditary renal diseases (e.g., cystinuria, Alport syndrome) which may affect both donor and recipient.
Tacrolimus & Ramadan: Patients must be counselled to maintain tacrolimus timing during Ramadan — consistent 12-hour intervals for twice-daily dosing are essential regardless of fasting. Missing doses risks rejection. Religious scholars permit medication taking during fasting for medical necessity.
CKD from T2DM in GCC: Diabetic nephropathy is the leading cause of ESRD requiring transplantation across GCC countries (highest diabetes prevalence globally). Prevention through glycaemic control is a major public health priority.
Heat/dehydration post-transplant: GCC climate increases risk of dehydration in transplant recipients — a risk factor for tacrolimus toxicity and graft injury. Patient education on adequate fluid intake in summer is essential.

MCQ Practice — Renal Transplant

Q1. A patient 10 days post renal transplant develops rising creatinine, oliguria, and mild graft tenderness. Tacrolimus level is therapeutic. What investigation is required to guide treatment?

A) Renal ultrasound only

B) Urine MC&S to rule out UTI

C) Renal allograft biopsy to determine rejection type

D) Increase tacrolimus dose empirically

✅ C — Biopsy is required to differentiate acute cellular vs antibody-mediated rejection (and exclude other causes like drug toxicity). Treatment differs: cellular rejection = IV methylprednisolone; ABMR = plasmapheresis + IVIG + rituximab. Empirical treatment without biopsy is inappropriate.

Q2. A renal transplant patient starts rifampicin for TB. The nurse should anticipate:

A) Increased tacrolimus levels — reduce dose

B) Decreased tacrolimus levels — increase monitoring frequency and likely dose increase required

C) No interaction — rifampicin does not affect tacrolimus

D) Rifampicin is contraindicated in transplant patients

✅ B — Rifampicin is a potent CYP3A4 inducer and significantly decreases tacrolimus levels, risking acute rejection. Tacrolimus trough levels must be monitored daily when starting rifampicin and dose usually needs substantial increase. Rifampicin is used for TB in transplant patients but requires very close monitoring.

Q3. Immediately post-renal transplant, the patient produces 500 mL of urine in the first hour. What is the appropriate fluid management?

A) Restrict IV fluids as this is excessive urine output

B) Give a bolus of Hartmann's 500 mL then reassess

C) Replace mL for mL with IV 0.9% NaCl to maintain fluid balance

D) Give IV furosemide 40mg to facilitate diuresis

✅ C — Post-transplant diuresis of 200–1000 mL/hr is expected and indicates graft function. Fluid must be replaced mL:mL to prevent hypovolaemia and graft injury (ATN from underperfusion). Standard protocol: 0.9% NaCl matched to UO + insensible losses.

Q4. Which prophylactic medication is routinely prescribed to renal transplant patients to prevent Pneumocystis jirovecii pneumonia (PCP)?

A) Fluconazole

B) Aciclovir

C) Co-trimoxazole (trimethoprim-sulfamethoxazole)

D) Ciprofloxacin

✅ C — Co-trimoxazole (trimethoprim-sulfamethoxazole) is the standard PCP prophylaxis for immunosuppressed transplant patients, typically given for 6–12 months post-transplant. It also provides additional protection against Toxoplasma and some bacterial infections. If sulfa-allergic: dapsone or atovaquone as alternatives.

Renal Transplant — Nursing Guide